Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | KCNQ3 | O43525 | 7/20 | 0.58 |
| ▸ | KCNQ2 | O43526 | 7/20 | 0.58 |
| ▸ | KCNE1 | P15382 | 7/20 | 0.58 |
| ▸ | KCNQ1 | P51787 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | LIPE | Q05469 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1235368 | 0.80 | HDAC1 (0.60) | RAB9AKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL7748111 | 0.80 | RAB9A (0.83) | RAB9ACYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL24178169 | 0.79 | ALDH1A1 (0.58) | RAB9ACYP1A2CYP2D6CYP2C19KCNQ3 | |
| SCHEMBL2302927 | 0.79 | ALDH1A1 (0.64) | RAB9ACYP1A2CYP2D6CYP2C19KCNQ3 | |
| SCHEMBL1233684 | 0.78 | KCNQ3 (0.60) | RAB9ACYP1A2CYP2D6CYP2C19KCNQ3 | |
| SCHEMBL6708115 | 0.77 | MEN1 (0.57) | RAB9ACYP1A2CYP2D6CYP2C19KCNQ3 | |
| SCHEMBL6708107 | 0.76 | F10 (0.56) | RAB9AKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL6708189 | 0.76 | NPC1 (0.60) | RAB9AKCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL11321129 | 0.75 | RAB9A (0.70) | RAB9ACYP1A2CYP2D6CYP2C19KDM4E | |
| SCHEMBL4063955 | 0.75 | NPC1 (0.62) | RAB9ACYP1A2CYP2C19KCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794397-B2 | ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2004-09-21 | — | — | US | claimed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | claimed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | claimed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | claimed |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | CYTOVIA, INC. | 2004-11-25 | — | — | US | disclosed |
| US-6794397-B2 | ANTICARCINOGENIC AGENTS | CYTOVIA, INC. | 2004-09-21 | — | — | US | disclosed |
| EP-1257536-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001055115-A1 | SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010185-A1 | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, BAD, CASP12 | RAB9A 1146/4885CYP1A2 1095/4885CYP2D6 1354/4885 |
| US-20040235846-A1 | Administering substituted nicotinamides and nicotinamide analogs for therapy of disorder responsive to the induction of apoptosis in an animal; anti-cancer agents | NAMPT, BAD, NNT | RAB9A 975/4885CYP1A2 2155/4885CYP2D6 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.